Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Employees - 6100,
CEO - Dr. Reshma Kewalramani FASN, M.D.,
Sector - Healthcare,
Country - US,
Market Cap - 124.29B
Altman ZScore(max is 10): 13.7, Piotroski Score(max is 10): 5, Working Capital: $6031800000, Total Assets: $22533200000, Retained Earnings: $9606800000, EBIT: 279100000, Total Liabilities: $6123600000, Revenue: $11005800000
AryaFin Target Price - $612.23 - Current Price $484.01 - Analyst Target Price $506.92
| Ticker | VRTX |
| Index | NDX, S&P 500 |
| Curent Price | 484.01 |
| Change | 0.11% |
| Market Cap | 124.29B |
| Average Volume | 1.46M |
| Income | -535.60M |
| Sales | 10.98B |
| Book Value/Share | 63.87 |
| Cash/Share | 23.83 |
| Dividend Est | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Employees | 6100 |
| Moving Avg 20days | -3.05% |
| Moving Avg 50days | 0.74% |
| Moving Avg 200days | 2.91% |
| Shares Outstanding | 256.94M |
| Earnings Date | Feb 10 AMC |
| Inst. Ownership | 93.30% |
| Price/Earnings | - |
| Forwad P/E | 23.32 |
| PE Growth | - |
| Price/Sales | 11.32 |
| Price/Book | 7.58 |
| Price/Cash | 20.31 |
| Price/FCF | - |
| Quick Ratio | 2.35 |
| Current Ratio | 2.69 |
| Debt/Equity | 0.11 |
| Return on Assets | -2.32% |
| Return on Equity | -3.15% |
| Return on Investment | -2.96% |
| Gross Margin | 86.07% |
| Ops Margin | -1.65% |
| Profit Margin | -4.88% |
| RSI | 44.44 |
| BETA(β) | 0.52 |
| From 52week Low | 28.10% |
| From 52week High | -6.90% |
| EPS | -2.20 |
| EPS next Year | 20.76 |
| EPS next Qtr | 4.26 |
| EPS this Year | 4174.03% |
| EPS next 5 Year | - |
| EPS past 5 Year | - |
| Sales past 5 Year | 22.39% |
| EPS Y/Y | -114.72% |
| Sales Y/Y | 11.64% |
| EPS Q/Q | -5.61% |
| Sales Q/Q | 14.56% |
| Sales Surprise | 4.59% |
| EPS Surprise | -0.90% |
| ATR(14) | 12.48 |
| Perf Week | -3.69% |
| Perf Month | -1.55% |
| Perf Quarter | 20.19% |
| Perf Year | 18.22% |
| Perf YTD | 20.19% |
| Target Price | 506.92 |
AryaFin Engine© - An AI FinTech Venture - 2024-25 Disclaimer